Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Deferred Revenue (2016 - 2021)

Historic Current Deferred Revenue for Syndax Pharmaceuticals (SNDX) over the last 7 years, with Q3 2021 value amounting to $12.4 million.

  • Syndax Pharmaceuticals' Current Deferred Revenue rose 71740.28% to $12.4 million in Q3 2021 from the same period last year, while for Sep 2021 it was $12.4 million, marking a year-over-year increase of 71740.28%. This contributed to the annual value of $1.5 million for FY2020, which is 0.0% changed from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Current Deferred Revenue of $12.4 million as of Q3 2021, which was up 71740.28% from $1.5 million recorded in Q2 2021.
  • In the past 5 years, Syndax Pharmaceuticals' Current Deferred Revenue registered a high of $12.4 million during Q3 2021, and its lowest value of $1.2 million during Q1 2017.
  • Over the past 5 years, Syndax Pharmaceuticals' median Current Deferred Revenue value was $1.5 million (recorded in 2018), while the average stood at $2.0 million.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Current Deferred Revenue tumbled by 356.01% in 2018 and then skyrocketed by 71740.28% in 2021.
  • Quarter analysis of 5 years shows Syndax Pharmaceuticals' Current Deferred Revenue stood at $1.6 million in 2017, then decreased by 3.56% to $1.5 million in 2018, then changed by 0.0% to $1.5 million in 2019, then changed by 0.0% to $1.5 million in 2020, then skyrocketed by 717.4% to $12.4 million in 2021.
  • Its Current Deferred Revenue stands at $12.4 million for Q3 2021, versus $1.5 million for Q2 2021 and $1.5 million for Q1 2021.